Amgen's Q2 Rebound: Sequential Gains in Enbrel and Otezla Look Better, but the Y/Y Hit Still Matters

Amgen's Q2 beat improved the picture, but it did not remove the headwinds

Amgen's latest quarter looks stronger on the headline: total revenues exceeded $10 billion and rose 10% year over year. That does not mean the near-term pressures disappeared. Management now has to build on this performance when it reports again on August 4, 2026. If the next update shows another clean beat but no clear stabilization in pricing and patent-expiry drag, investors may conclude the rebound was real but still fragile.

The bullish case and the caution case

The bullish case is straightforward. A portfolio of this size can still generate serious scale, and Amgen was able to point to breadth across multiple franchises rather than rely on a single hero product. That makes the quarter more encouraging than a narrow hit driven by one drug.

The caution case is that a good quarter is not the same as a repaired business. Pre-print expectations already highlighted price declines for some products and higher 340B utilization as factors that could offset volume gains. The real question is whether Amgen is entering a cleaner growth phase or simply posting a stronger snapshot inside an otherwise difficult backdrop.

Portfolio breadth helped Q2, but pricing and patent expiry still matter

The quarter improves the picture, but it does not fully resolve the debate. Investors still need to see whether growth is becoming more durable across the portfolio or whether the faster products are simply doing more of the work to offset older drag.

Volume improved, but price mix still mattered

Q1 already showed the underlying mix. Amgen posted 9% volume growth, but that was only partially offset by 2% lower net selling price and 2% from lower inventory levels. In other words, more units were moving, but not all sales were holding full price. A single quarter of volume strength is encouraging, but it is not enough by itself to prove the pricing backdrop is fixed.

Q2 made the portfolio shift clearer. Amgen said six key growth drivers grew at an aggregate rate of 26% year-over-year and represented nearly 70% of second quarter product sales. It also said 22 products delivered double-digit sales growth and 17 products annualized at more than $1 billion based on second quarter sales. That looks more like a broad franchise than a one-product story.

The structural pressures have not gone away

Even with better momentum elsewhere, Amgen still faces meaningful pressure from older assets and pricing headwinds:

• Price declines for some products and increases in 340B program utilization were expected to offset part of the volume gain.
• Prolia and Xgeva lost patent exclusivity, and accelerated sales erosion is expected over the remainder of 2026 as several biosimilars have been launched globally.
• Even in Q2, Prolia and XGEVA combined delivered $1.1 billion in second quarter sales, so this is not a minor side issue.

The practical takeaway is simple: Amgen's income stream looks healthier, but the drag from patent expirations and pricing still matters.

Enbrel and Otezla are still a verification point

The released highlights support a broad portfolio story, but they do not let us fully confirm Enbrel or Otezla sequential Q2 rebounds on their own. If management made that case in the full release or call, it still needs to be verified there. For now, the cleaner signal is the wider mix: six key growth drivers are doing more of the work, and double-digit growth is spread across more products.

What would make the rebound more convincing

The next proof point is persistence. If the growth mix stays broad and the pressure from Prolia/Xgeva and pricing stops getting worse, investors have a stronger case for paying up. If those pressures start gaining weight again, the quarter will look more like a strong snapshot than a durable turn.

The next report matters more than the headline beat

With Amgen set to report again on August 4, 2026, the more useful question is not whether the company can beat estimates again. It is whether the business can show that its stronger quarter was the start of something more sustained. Amgen has already earned some benefit of the doubt: it reported $3.5 billion in free cash flow and a 48% non-GAAP operating margin, while also raising full-year guidance. That means the company does not need a heroic quarter to remain relevant. It needs consistency.